Spondyloarthritis & psoriatic arthritis
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations
Authors' conclusion
Advanced therapies are not equally efficacious across these related conditions, with dosing regimens and safety varying.
Study context
- Population
- Randomized controlled trials (RCTs) of advanced therapies in Crohn disease (CD), ulcerative colitis (UC) and noninfectious uveitis, related conditions in patients with psoriatic arthritis (PsA); MEDLINE, Embase, Cochrane Library, February 2013 to August 202032 RCTs
- Comparison
- Advanced therapies (tumor necrosis factor inhibitor (TNFi), IL-12/23i, Janus kinase inhibitors (JAKi), IL-23i, IL-17i) for concomitant CD, UC or noninfectious uveitis in PsA
- Outcome
- Efficacy and safety of advanced therapies for CD, UC and noninfectious uveitis
Methodological detailsupdated systematic literature review, Grading of Recommendations Assessment, Development, and Evaluation (GRADE) quality assessment
- Updated systematic literature review
- GRADE quality assessment
Pooled result
As reported in the abstract
Efficacy and safety of advanced therapies in CD, UC and uveitis
- Eligible RCTs: 12 for CD, 15 for UC, 5 for uveitis
- TNFi class appears efficacious and safe across CD, UC and uveitis, with the exception of etanercept
- IL-12/23i efficacious for CD and UC
- Phase II and III RCTs of JAKi and IL-23i in CD and UC promising in efficacy and safety
- IL-17i must be used with great caution in PsA at high risk of inflammatory bowel disease (IBD)
- RCTs in uveitis mainly studied adalimumab
Original publication
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. Published 1 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →